Wird geladen...
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 products that relate to efficacy and safety. For...
Gespeichert in:
Veröffentlicht in: | MAbs |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
Taylor & Francis
2017
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5419076/ https://ncbi.nlm.nih.gov/pubmed/28296619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1305530 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|